EUVIMEDEUVIMED entdecken
Crossref

Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease–Directed Risk-Based Therapy

Sweta Rajpal iD, Gaurav Chatterjee iD, Prasanna Bhanshe, Vishram Terse iD, Swapnali Joshi, Shruti Chaudhary, Dhanalaxmi Shetty iD, Purvi Mohanty, Chetan Dhamne iD, Prashant Ramesh Tembhare iD, Shyam Srinivasan iD, Akanksha Chichra und 6 weitere

JCO Global Oncology · 2026

DOI: 10.1200/go-25-00665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Sweta Rajpal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India. Hauptthemen laut MEDLINE: Neoplasm, Residual, Genomics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE WHO5 (2022) classification of B-lymphoblastic leukemia (B-ALL) incorporates several novel entities requiring high-throughput sequencing for their accurate characterization. The clinical relevance of this classification in the context of contemporary measurable residual disease (MRD)–directed therapy is unclear. METHODS We analyzed 533 pediatric B-ALL uniformly treated with Indian Collaborative Childhood Leukaemia group (ICiCLe)-ALL-14 protocol as defined by WHO-2016 and reclassified them as per WHO5 using targeted sequencing, FISH, and cytogenetics. RESULTS Subtype-defining genomic abnormalities were identified in 81.2% of the cohort as per the WHO5 classification. Among the new subtypes, PAX5 alt and MEF2D -r were associated with a trend toward an inferior 3-year event-free survival (EFS) of 32.8% ( P = .003) and 33.7% ( P = .091), respectively. We developed a three-tier genomic risk stratification model incorporating 15 genomic subtypes and the IKZF1 deletion. Children with standard (SGR), intermediate (IGR), and high genomic risk (HGR) demonstrated 3-year EFS of 80.4%, 59.3%, and 45.8% ( P < .0001), and 3-year overall survival of 89.6%, 75.3%, and 62.3% ( P < .0001), respectively. Genomic risk further identified heterogeneous outcomes among ICiCLe risk groups ( P < .0001). SGR was associated with superior EFS irrespective of MRD status (3-year EFS 80.5% in postinduction [PI] MRD–negative v 80.8% PI-MRD–positive patients, P = .530). On multivariable analysis, genomic risk (hazard ratio [HR], 1.7 [95% CI, 1.41 to 2.01]; P < .0001), initial ICiCLe risk (HR, 1.3 [95% CI, 1.06 to 1.49]; P = .009), and PI-MRD (HR, 2.2 [95% CI, 1.66 to 2.90]; P < .0001) independently predicted EFS. CONCLUSION The study demonstrates the potential role of genomic risk stratification, in conjunction with MRD, in stratifying patients into clinically relevant risk categories.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualGenomicsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansFemaleMaleChild, PreschoolChildInfantAdolescent

Autor:innen und Institutionen

  • Department of Haematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
  • Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
  • Pediatric Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.

ORCID-Profile: Sweta Rajpal, Gaurav Chatterjee, Vishram Terse, Dhanalaxmi Shetty, Chetan Dhamne, Prashant Ramesh Tembhare, Shyam Srinivasan, Nirmalya Roy Moulik, Shripad Banavali, Gaurav Narula, Papagudi G Subramanian, Nikhil Patkar

Zitieren

APA

Rajpal, S., Chatterjee, G., Bhanshe, P., Terse, V., Joshi, S., Chaudhary, S., Shetty, D., Mohanty, P., Dhamne, C., Tembhare, P. R., Srinivasan, S., Chichra, A., Moulik, N. R., Banavali, S., Gujral, S., Narula, G., Subramanian, P. G., & Patkar, N. (2026). Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease–Directed Risk-Based Therapy. JCO Global Oncology. https://doi.org/10.1200/go-25-00665

Vancouver

Rajpal S, Chatterjee G, Bhanshe P, Terse V, Joshi S, Chaudhary S, et al. Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease–Directed Risk-Based Therapy. JCO Global Oncology. 2026. doi:10.1200/go-25-00665

BibTeX
@article{Rajpal2026,
  author = {Rajpal, Sweta and Chatterjee, Gaurav and Bhanshe, Prasanna and Terse, Vishram and Joshi, Swapnali and Chaudhary, Shruti and Shetty, Dhanalaxmi and Mohanty, Purvi and Dhamne, Chetan and Tembhare, Prashant Ramesh and Srinivasan, Shyam and Chichra, Akanksha and Moulik, Nirmalya Roy and Banavali, Shripad and Gujral, Sumeet and Narula, Gaurav and Subramanian, Papagudi G and Patkar, Nikhil},
  title = {Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease–Directed Risk-Based Therapy},
  journal = {JCO Global Oncology},
  year = {2026},
  doi = {10.1200/go-25-00665}
}
Kostenlos starten →